Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...

Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. HSK31858 given as 20 mg or 40 mg performed better than ...

Please provide your email address to receive an email when new articles are posted on . The FDA based brensocatib’s approval on phase 3 ASPEN and phase 2 WILLOW trial results. This marks the first ...

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...

Miami (March 12, 2025) – The Bronchiectasis and NTM Association has accepted 27 Care Center and six Clinical Associate Center sites in 23 states and the District of Columbia into the new ...

New research underscores how air pollution and temperature extremes amplify risks for bronchiectasis patients, pointing to critical measures for safeguarding vulnerable groups. Study: Association of ...

One woman's journey from an unexpected diagnosis to learning how to manage a chronic, progressive lung disease. When Lavonda was told she had bronchiectasis, she didn't know what the word meant. "I ...